Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include the US Food and Drug Administration acceptance of a New Drug Application for rusfertide in polycythemia vera, topline data from the phase 3 AFFIRM study of risankizumab (Skyrizi) subcutaneous induction in Crohn’s disease, phase 3 data for ralinepag in pulmonary arterial hypertension, phase 2 SUMMIT trial data on bezuclastinib in nonadvanced systemic mastocytosis, and ACTIVATE trial data on vaginal seeding in cesarean-delivered infants.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here’s your quick dive into the top stories for the week of March 01, 2026—let’s jump in!

FDA Accepts New Drug Application for Rusfertide, Grants Priority Review In Polycythemia Vera

On March 2, 2026, the FDA accepted and granted Priority Review to an NDA for rusfertide for polycythemia vera based on results from the phase 3 VERIFY, phase 2 REVIEW, and long-term extension THRIVE study. Announced by Takeda and Protagonist, the Prescription Drug User Fee Act (PDUFA) target action date is set for the third quarter of this calendar year.

AFFIRM: Risankizumab (Skyrizi) Subcutaneous Induction Achieves Primary Endpoints in Crohn’s Disease

On March 2, 2026, AbbVie announced positive topline results from the phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (Skyrizi) subcutaneous (SC) induction treatment versus placebo in adult patients with moderately to severely active Crohn's disease. Findings showed significantly greater proportions of patients treated with risankizumab SC induction achieved the co-primary endpoints of Crohn's Disease Activity Index clinical remission and endoscopic response at week 12 compared to placebo.

ADVANCE OUTCOMES: Ralinepag Outperforms Placebo in Slowing Disease Progression in PAH

On March 2, 2026, United Therapeutics Corporation announced that its investigative prostacyclin receptor agonist ralinepag met its primary endpoint of reducing worsening clinical events in patients with pulmonary arterial hypertension in the phase 3 ADVANCE OUTCOMES study. The study additionally met several important secondary endpoints, including increasing odds of clinical improvement by 47%, in predominantly pre-treated patients with pulmonary arterial hypertension.

SUMMIT: Bezuclastinib Delivers Durable, Deepening Symptom Relief in NonAdvSM, With Cem Akin, MD

Bezuclastinib, an oral, highly selective type 1 KIT inhibitor, has demonstrated that clinically meaningful symptom improvement not only holds but continues to deepen out to 48 weeks of treatment in patients with nonadvanced systemic mastocytosis (NonAdvSM), with every assessed symptom domain showing progressive gains over the treatment course. Data from the pivotal, multicenter, randomized, double-blind, placebo-controlled phase 2 SUMMIT trial were presented at the 

American Academy of Allergy, Asthma & Immunology (AAAAI)

 2026 Annual Meeting held in Philadelphia, Pennsylvania.

Vaginal Seeding Partially Modifies Infant Microbiome in ACTIVATE, With Jose Clemente, PhD

Vaginal seeding in cesarean-delivered infants was associated with altered early gut microbiome patterns and differences in food sensitization at 12 months, according to late-breaking ACTIVATE trial data presented at the 2026 AAAAI Annual Meeting in Philadelphia. Jose Clemente, PhD, associate professor of Genetics and Genomics and Immunology at the Icahn School of Medicine at Mount Sinai, explains the biologic rationale behind the trial and what the findings may mean for clinicians.

Articles

FDA granted Priority Review for rusfertide in polycythemia vera, with an NDA supported by phase 3/2 and extension datasets and a PDUFA decision targeted for Q3. In Crohn’s disease, subcutaneous risankizumab induction met co-primary endpoints at week 12, demonstrating clinical remission and endoscopic response versus placebo. In pulmonary arterial hypertension, ralinepag reduced worsening clinical events and improved odds of clinical improvement in largely pre-treated patients. Bezuclastinib showed durable, deepening symptom benefit through 48 weeks in nonadvanced systemic mastocytosis. Vaginal seeding modestly shifted infant microbiome trajectories and food sensitization signals.

Stay updated with the latest healthcare breakthroughs, FDA actions, and new trial data, in this week’s essential news roundup.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Hematology

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

The HCPFive: Top News for Healthcare Providers from the Week of 03/01

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

February 2026 brought a series of notable developments in psychiatry, spanning regulatory approvals, late-stage clinical trial milestones, and new research aimed at improving care for patients with complex mood disorders. From advances in psychedelic-assisted therapies to new pharmacologic options for serious mental illness, the month highlighted the evolving treatment landscape for conditions such as schizophrenia, bipolar disorder, and major depressive disorder.

Among the most significant updates was the approval of milsaperidone (Bysanti) by the US Food and Drug Administration (FDA) for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for schizophrenia in adults, expanding the range of first-line treatment options available to clinicians. Meanwhile, investigational psychedelic therapies continued to generate momentum, with COMP360 psilocybin meeting the primary endpoint in a second phase 3 trial for treatment-resistant depression and early clinical data suggesting antidepressant effects from intravenous SPL026 in patients with major depressive disorder.

Beyond drug development, new research also offered insights into clinical decision-making and emerging neuromodulation approaches. Studies examining predictors of relapse following antidepressant discontinuation and the age-related effects of magnetic seizure therapy in treatment-resistant depression underscore the ongoing effort to refine personalized care strategies for patients with difficult-to-treat psychiatric conditions.

In this psychiatry month in review, we highlight the key approvals, clinical trial updates, and research findings that shaped the month of February.

FDA Approves Milsaperidone for Acute Bipolar I Disorder, Schizophrenia

On February 20, 2026, the FDA approved Vanda Pharmaceuticals’ milsaperidone (Bysanti) tablets as a first line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults. In clinical studies, milsaperidone demonstrated bioequivalence to iloperidone across the therapeutic dosing spectrum. Commercial availability is expected by Q3 2026.

Intravenous DMT (SPL026) Demonstrates Significant MDD Reduction in Phase 2a Trial

On February 20, 2026, Helus Pharma announced the publication of results from a phase 2a randomized, placebo-controlled clinical trial evaluating SPL026 in participants with moderate-to-severe major depressive disorder. The study met its primary endpoint for statistically significant and clinically meaningful reductions in depressive symptoms at 2 weeks, as measured by the Montgomery-Åsberg Depression Rating Scale in participants treated with SPL026 compared with placebo. Helus Pharma does not plan to advance intravenous SPL026 in its current form but will use the mechanistic and clinical insights generated from the trial to continue to inform the Company’s HLP004 development program.

COMP360 Psilocybin Meets Primary Endpoint in Second Phase 3 Trial for TRD

On February 17, 2026, Compass Pathways announced that its investigational synthetic psilocybin formulation, COMP360, met the primary endpoint in the second pivotal phase 3 trial evaluating the therapy in adults with treatment-resistant depression. In the COMP006 study, a pair of 25-mg doses administered 3 weeks apart yielded a statistically significant reduction in depressive symptom severity at week 6 compared with a 1-mg dose control, reinforcing findings from the companion COMP005 trial and advancing the program toward regulatory submission.

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

Recent research shows delay discounting did not predict relapse after antidepressant discontinuation in patients with remitted major depressive disorder, despite a modest association with residual depressive symptoms. Findings from the multi-site longitudinal study suggest a lack of reliable tools for predicting relapse and emphasize the importance of individualized, shared decision-making when counseling patients.

MST Shows Age-Related Differences in MDD Outcomes, With Lina Jia, MD, PhD

New data suggest adolescents with treatment-resistant major depressive disorder receiving magnetic seizure therapy (MST) may experience faster symptom improvement, fewer cognitive adverse events, and better overall tolerability compared to adults. Findings from the prospective comparative study address a critical evidence gap in neuromodulation for depression, as most existing data are derived from adult populations despite important developmental, neurobiological, and safety considerations in younger patients.

February 2026 psychiatry milestones spanned an FDA approval, pivotal psychedelic trial success, and clinically focused research on relapse risk and neuromodulation. Milsaperidone gained US approval as a first-line option for acute manic/mixed episodes in bipolar I disorder and for adult schizophrenia, with launch expected Q3 2026. Psychedelic programs advanced, including positive phase 3 outcomes for COMP360 psilocybin in treatment-resistant depression and phase 2a signal for IV DMT (SPL026) in major depressive disorder, informing next-generation development.

The FDA approval of milsaperidone and a pair of positive trials in depression signal a month of progress in psychiatry.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

5 Psychiatry Headlines You Missed in February 2026

Karen Maddox, MD, MPH, is a professor of medicine and public health and co-director of the Center for Advancing Health Services, Policy & Economics Research at the Washington University School of Medicine.

6 in 10 US Women Predicted to Have Cardiovascular Disease by 2050, With Karen Maddox, MD, MPH

The prevalence of cardiovascular risk factors and 

 in women is projected to increase dramatically through 2050, based on a recent statement from the American Heart Association (AHA).

Currently, >62 million women in the US are living with some form of CVD. Additionally, some health factors, including high blood pressure, 

, are increasing among young girls aged 2-19. Based on current trends and with no further intervention, these numbers are only expected to rise.

“We really wanted to provide a 30,000-foot overview of where we’re headed in women’s cardiovascular health in the US,” Karen Maddox, MD, MPH, a professor of medicine and public health and co-director of the Center for Advancing Health Services, Policy & Economics Research at the Washington University School of Medicine, told 

 in an exclusive interview. “We looked at both cardiovascular risk factors and events, and took what we understand about the trends and all of those things leading up to today and tried to project forward through 2050 to understand where we’re going.”

Maddox and colleagues estimated the prevalence of suboptimal levels of each component of the AHA’s Life’s Essential 8, as well as the prevalence of 4 major cardiovascular diseases, including coronary heart disease (CHD), 

, all 4 of which were collectively described as CVD. The baseline prevalence of each disease was estimated via data from the 2015-2020 prepandemic National Health and Nutrition Examination Survey (NHANES).

Additional NHANES data from 2010-2020 was utilized to estimate growth or decline in age-adjusted prevalence of risk factors and clinical CVD, applying these rates to age/sex/race and ethnicity-specific prevalence for 2020-2050. The team then combined estimated prevalence by age/sex/race and ethnicity with the 2010 Census projections of population counts for 2020-2050 to generate the number of women and girls with each condition for this time period.

Among the Life’s Essential 8 components, Maddox and colleagues determined that 

 will increase from 48.6% in 2020 to 59.1% in 2050. Diabetes will also increase from 14.9% to 25.3%, while obesity will rise from 43.9% to 61.2%. However, hypercholesterolemia is projected to decline from 42.1% to 22.3%. Suboptimal health behaviors were largely projected to improve over time, including suboptimal diet (49% to 47.6%), inadequate physical activity (39.8% to 28.6%), and smoking (13.8% to 7.2%). However, inadequate sleep will worsen, rising from 40.3% to 42.2%.

Overall CVD rates were all predicted to increase as well, with CHD rising from 6.85% to 8.21%, HF increasing from 2.45% to 3.6%, stroke rising from 4.14% to 6.74%, and AF from 1.58% to 2.31%. Additionally, total CVD will rise from 10.7% to 14.4%.

When divided by racial, ethnic, and age group, Maddox and colleagues noted that Black women had the highest baseline and projected prevalence of inadequate sleep and poor diet, while Asian women had the highest projected prevalence of inadequate physical activity. Younger women – 20-44 years – had the highest prevalence of poor diet and smoking, but the lowest of inadequate physical activity. Poor sleep was more prevalent among the oldest women, who were ≥80 years.

Ultimately, investigators determined that nearly 1 in 3 women 22-44 years of age will have some type of cardiovascular disease by 2050, which marks a significant increase from <1 in 4 currently. Of these, 1 in 6 women in the US will have some type of cardiovascular disease, largely driven by rapidly increasing rates of high blood pressure.

“The issue is that we don’t act on things when we find them, and we don’t necessarily get everyone the recommended guidelines,” Maddox said. “Many times, when someone young is found to have high blood pressure, we don’t take these very seriously, and we say they could lose some weight or exercise more and come back in a year or two.”

Editors’ Note: Maddox reports no relevant disclosures.

Joynt Maddox KE, Reynolds HR, Adedinsewo D, et al. Forecasting the burden of cardiovascular disease and stroke in women in the United States through 2050: A scientific statement from the American Heart Association. Circulation. Published online February 25, 2026. 

American Heart Association. 6 in 10 US women projected to have at least one type of cardiovascular disease by 2050. 

. February 25, 2026. Accessed March 6, 2026. 

https://www.eurekalert.org/news-releases/1117116

Videos

Maddox discusses the AHA’s recent statement indicating that, should current trends continue, 6 in 10 US women will have cardiovascular disease by 2050.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Arrhythmia

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Barbara Gillespie, MD, is Chief Medical and Strategy Officer of the International Society of Glomerular Disease and Adjunct Professor at the University of North Carolina.

Tobias Huber, MD, is President of the International Society of Glomerular Disease, Chair of the Center of Internal Medicine; Director of the III. Department of Medicine (Nephrology, Rheumatology, Endocrinology and Transplantation); and Director of the Hamburg Center for Kidney Health at the University Medical Center Hamburg-Eppendorf.

Clinical Trial Summit 2026: Advanced Therapies, Equity, and a Global Outlook for Glomerular Disease

The final episode looks ahead, weaving together summit planning, 2026 goals, cutting-edge therapies, and global equity.

Gillespie previews the International Society of Glomerular Disease (ISGD)’s inaugural Clinical Trial Summit in Galveston, Texas. Designed as a multi-stakeholder meeting, it will bring together basic scientists, trialists, venture capital, regulators, healthcare leaders, patients, study coordinators, and fellows. The format is intentionally interactive, aiming to break silos and “break barriers” in clinical trials.

Huber then proposes a “game” where each shares what they most look forward to by 2026. Their rapid-fire wishes include:

Implementing FSGS surrogate endpoints and widely sharing the work already completed.

Making substantial progress in membranous nephropathy endpoints, including integrating PLA2R titers into qualified surrogate measures.

Defining IgAN 2.0 trial designs as new drugs become standard of care, and learning how to combine multiple approved therapies targeting different points in the disease cascade.

Adapting hierarchical composite endpoints (HCEs) from cardiology, blending clinical outcomes, symptoms, and biomarkers to better reflect patient experience.

Advancing molecular stratification and endotyping of diseases via high-resolution tissue technologies, to eventually replace coarse histologic classifications.

The conversation then turns to cell and gene therapies, referencing an earlier KHI meeting with the 

 Center for Biologics Evaluation and Research (CBER) leaders and the approval of gene therapy for 

They anticipate cell therapies for diabetic kidney disease and membranous nephropathy, as well as gene therapy approaches for IgA nephropathy (IgAN) and Alport syndrome. They determine that success will require close collaboration with hematology and oncology teams already experienced with these modalities.

Huber closes with a reminder that all this high-end innovation must be matched by basic improvements in awareness and early detection, such as routine proteinuria screening, and by solutions for low- and middle-income countries. 

Gillespie adds a vision of glomerular disease centers of excellence, an idea long championed by her mentor Ron Falk, MD, and celebrates the growing cross-society collaboration that will be needed to turn glomerular disease into glomerular health worldwide.

, Chief Medical and Strategy Officer of the International Society of Glomerular Disease and Adjunct Professor at the University of North Carolina

, President of the International Society of Glomerular Disease, Chair of the Center of Internal Medicine; Director of the III. Department of Medicine (Nephrology, Rheumatology, Endocrinology and Transplantation); and Director of the Hamburg Center for Kidney Health at the University Medical Center Hamburg-Eppendorf

Editors’ Note: Gillespie reports no relevant disclosures. Huber reports relevant disclosures with Boehringer Ingelheim, Novartis, Alexion, Pfizer, Retrophin-Travere, and Fresenius Medical Care.

Gale D. RaDaR Validation Confirms PARASOL Findings on FSGS Surrogate Endpoint, with Daniel Gale, PhD, MB BChir. HCPLive. Published June 7, 2025. Accessed March 6, 2026. https://www.hcplive.com/view/radar-validation-confirms-parasol-findings-on-fsgs-surrogate-endpoint

Radhakrishnan J. New Guidelines and Novel Therapies in IgA Nephropathy, With Jai Radhakrishnan, MD. HCPLive. Published 2025. Accessed March 6, 2026. 

https://www.hcplive.com/view/new-guidelines-and-novel-therapies-in-iga-nephropathy-with-jai-radhakrishnan-md

Experts outline a 2026 vision for glomerular disease care, including new endpoints, combination therapies, and gene therapy advances.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Strategic Alliance Partnership

Clinical Trial Summit 2026: Advanced Therapies, Equity, Global Outlook For Glomerular Diseases

Parasol, Endpoints, and Rethinking Clinical Trials in Glomerular Disease

In this episode, the conversation broadens to the PARASOL framework and the evolving science of endpoints and trial design across glomerular diseases.

Gillespie briefly defines PARSOL, which is French for umbrella, as a unifying initiative conceived with leaders like Laurel Damashek to protect and guide the community toward better trial designs and therapeutic options across multiple diseases. PARASOL 1.0 focused on focal segmental glomerulosclerosis (FSGS), and newer extensions now target membranous nephropathy and APOL1-mediated kidney disease, with ambitions to cover many glomerular diseases over the coming decade.

The core philosophy of PARASOL is collaborative data sharing. For example, rather than each company independently shouldering the burden of building evidence for regulatory endpoints, sponsors with competing drugs work together, pooling clinical trial and registry data to evaluate potential surrogate endpoints. Gillespie underscores the importance of this shift, echoing other leading voices in the field who advocate for collaboration as essential to progress in rare and complex diseases.

Gillespie then gives a concise tutorial on endpoints:

In regulatory terms, endpoints must reflect how a patient feels, functions, or survives.

Validated surrogate endpoints (e.g., LDL cholesterol in atherosclerotic disease) have strong, long-term data linking biomarker changes to clinical outcomes.

Reasonably likely surrogate endpoints support accelerated approval, such as proteinuria reductions in IgA nephropathy.

Candidate surrogate endpoints, the focus of Parasol, are being evaluated for their potential to move up the hierarchy.

She notes that while some sponsors try to copy-paste the IgA nephropathy (IgAN) “recipe” to other diseases, this is inappropriate because each glomerular disease has unique pathobiology and mechanisms of action. Hence, disease-specific PARASOL projects for FSGS, membranous, APOL1, and beyond.

The episode also touches on Alport syndrome, where the ASSENT initiative is playing a similar endpoint-defining role, with roughly 45 companies interested.

Finally, Gillespie discusses practical trial challenges, including limited numbers of glomerular specialists, recruitment bottlenecks, and the need to mobilize community nephrologists. She highlights clinical trial boot camps that train new investigators and shows how collaborations with patient organizations are critical for dissemination, pricing, and implementation once drugs are approved.

Neuen B, Wadhwani, S. Kidney Compass: The PARASOL Initiative, with Laura Mariani, MD, MS, and Daniel Gale, PhD, MB BChir. Hcplive.com. Published December 11, 2024. Accessed March 6, 2026. https://www.hcplive.com/view/kidney-compass-the-parasol-initiative-with-laura-mariani-md-ms-and-daniel-gale-phd-mb-bchir

Neuen B. Kidney Compass: PARASOL Findings and Implications for FSGS. HCPLive. Published 2024. Accessed March 6, 2026. https://www.hcplive.com/view/kidney-compass-parasol-findings-and-implications-for-fsgs

The PARASOL initiative is reshaping glomerular disease trials through shared data and improved surrogate endpoints.

PARASOL, Endpoints, and Rethinking Clinical Trials in Glomerular Disease

PLA2R antibodies are advancing precision care in membranous nephropathy and informing new surrogate endpoints through PARASOL.

PLA2R, Membranous Nephropathy, and the PARASOL Membranous Project

Anti-nephrin autoantibodies are redefining minimal change disease and enabling more precise, steroid-sparing treatment strategies.

Anti-Nephrin Autoantibodies, Precision in Nephrotic Syndrome

APOL1 kidney disease highlights the need for community trust, increased screening, and stronger clinical trial participation.

APOL1 Kidney Disease: Community, Trust, and Trial Participation

Rapid advances in glomerular disease, from single-cell tech to biomarkers and phase 3 trials, are reshaping diagnosis and treatment.

ISGD and the Fastest 5 Years in Glomerular Disease

Phase 2 ALPHA-SOLAR data presented at AAAAI 2026 show navenibart provides >95% median attack reduction in HAE with favorable safety for 3- and 6-month prophylaxis.


Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Navenibart at 3- and 6-Month Dosing Reduces HAE Attacks, With Adil Adatia, MD

This FDA News Month in Review provides a round-up of regulatory decisions from February 2026.

FDA News

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

6 FDA Headlines You Missed in February 2026

This Q&A with Neal Bhatia, MD, features a discussion conducted regarding GLP-1 use in patients with psoriasis and obesity or overweight.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Q&A on Treating Psoriasis, Obesity with Tirzepatide and Ixekizumab, With Neal Bhatia, MD

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

In this segment of Liver Lineup, experts discuss the complexity of hepatitis B guidelines and why it’s important to empower clinicians and expand care beyond specialists.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Are We Making Hepatitis B Treatment Too Complicated?

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

This month in review features 7 allergy headlines in February 2026: FDA's decision on Dupilumab for AFRS, late-breaking data presented at AAAAI, & more.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

7 Allergy Headlines You Missed in February 2026

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline results from the TRIUMPH-4 trial, demonstrating retatrutide's efficacy in promoting weight loss.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Latest News

The HCPFive: Top News for Healthcare Providers from the Week of 03/01

5 Psychiatry Headlines You Missed in February 2026

6 in 10 US Women Predicted to Have Cardiovascular Disease by 2050, With Karen Maddox, MD, MPH

Clinical Trial Summit 2026: Advanced Therapies, Equity, Global Outlook For Glomerular Diseases

PARASOL, Endpoints, and Rethinking Clinical Trials in Glomerular Disease